Cargando…
An intermediate-effect size variant in UMOD confers risk for chronic kidney disease
The kidney-specific gene UMOD encodes for uromodulin, the most abundant protein excreted in normal urine. Rare large-effect variants in UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD), while common low-impact variants strongly associate with kidney function and the risk of ch...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388113/ https://www.ncbi.nlm.nih.gov/pubmed/35947615 http://dx.doi.org/10.1073/pnas.2114734119 |
_version_ | 1784770151754760192 |
---|---|
author | Olinger, Eric Schaeffer, Céline Kidd, Kendrah Elhassan, Elhussein A. E. Cheng, Yurong Dufour, Inès Schiano, Guglielmo Mabillard, Holly Pasqualetto, Elena Hofmann, Patrick Fuster, Daniel G. Kistler, Andreas D. Wilson, Ian J. Kmoch, Stanislav Raymond, Laure Robert, Thomas Eckardt, Kai-Uwe Bleyer, Anthony J. Köttgen, Anna Conlon, Peter J. Wiesener, Michael Sayer, John A. Rampoldi, Luca Devuyst, Olivier |
author_facet | Olinger, Eric Schaeffer, Céline Kidd, Kendrah Elhassan, Elhussein A. E. Cheng, Yurong Dufour, Inès Schiano, Guglielmo Mabillard, Holly Pasqualetto, Elena Hofmann, Patrick Fuster, Daniel G. Kistler, Andreas D. Wilson, Ian J. Kmoch, Stanislav Raymond, Laure Robert, Thomas Eckardt, Kai-Uwe Bleyer, Anthony J. Köttgen, Anna Conlon, Peter J. Wiesener, Michael Sayer, John A. Rampoldi, Luca Devuyst, Olivier |
author_sort | Olinger, Eric |
collection | PubMed |
description | The kidney-specific gene UMOD encodes for uromodulin, the most abundant protein excreted in normal urine. Rare large-effect variants in UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD), while common low-impact variants strongly associate with kidney function and the risk of chronic kidney disease (CKD) in the general population. It is unknown whether intermediate-effect variants in UMOD contribute to CKD. Here, candidate intermediate-effect UMOD variants were identified using large-population and ADTKD cohorts. Biological and phenotypical effects were investigated using cell models, in silico simulations, patient samples, and international databases and biobanks. Eight UMOD missense variants reported in ADTKD are present in the Genome Aggregation Database (gnomAD), with minor allele frequency (MAF) ranging from 10(−5) to 10(−3). Among them, the missense variant p.Thr62Pro is detected in ∼1/1,000 individuals of European ancestry, shows incomplete penetrance but a high genetic load in familial clusters of CKD, and is associated with kidney failure in the 100,000 Genomes Project (odds ratio [OR] = 3.99 [1.84 to 8.98]) and the UK Biobank (OR = 4.12 [1.32 to 12.85). Compared with canonical ADTKD mutations, the p.Thr62Pro carriers displayed reduced disease severity, with slower progression of CKD and an intermediate reduction of urinary uromodulin levels, in line with an intermediate trafficking defect in vitro and modest induction of endoplasmic reticulum (ER) stress. Identification of an intermediate-effect UMOD variant completes the spectrum of UMOD-associated kidney diseases and provides insights into the mechanisms of ADTKD and the genetic architecture of CKD. |
format | Online Article Text |
id | pubmed-9388113 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | National Academy of Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-93881132022-08-19 An intermediate-effect size variant in UMOD confers risk for chronic kidney disease Olinger, Eric Schaeffer, Céline Kidd, Kendrah Elhassan, Elhussein A. E. Cheng, Yurong Dufour, Inès Schiano, Guglielmo Mabillard, Holly Pasqualetto, Elena Hofmann, Patrick Fuster, Daniel G. Kistler, Andreas D. Wilson, Ian J. Kmoch, Stanislav Raymond, Laure Robert, Thomas Eckardt, Kai-Uwe Bleyer, Anthony J. Köttgen, Anna Conlon, Peter J. Wiesener, Michael Sayer, John A. Rampoldi, Luca Devuyst, Olivier Proc Natl Acad Sci U S A Biological Sciences The kidney-specific gene UMOD encodes for uromodulin, the most abundant protein excreted in normal urine. Rare large-effect variants in UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD), while common low-impact variants strongly associate with kidney function and the risk of chronic kidney disease (CKD) in the general population. It is unknown whether intermediate-effect variants in UMOD contribute to CKD. Here, candidate intermediate-effect UMOD variants were identified using large-population and ADTKD cohorts. Biological and phenotypical effects were investigated using cell models, in silico simulations, patient samples, and international databases and biobanks. Eight UMOD missense variants reported in ADTKD are present in the Genome Aggregation Database (gnomAD), with minor allele frequency (MAF) ranging from 10(−5) to 10(−3). Among them, the missense variant p.Thr62Pro is detected in ∼1/1,000 individuals of European ancestry, shows incomplete penetrance but a high genetic load in familial clusters of CKD, and is associated with kidney failure in the 100,000 Genomes Project (odds ratio [OR] = 3.99 [1.84 to 8.98]) and the UK Biobank (OR = 4.12 [1.32 to 12.85). Compared with canonical ADTKD mutations, the p.Thr62Pro carriers displayed reduced disease severity, with slower progression of CKD and an intermediate reduction of urinary uromodulin levels, in line with an intermediate trafficking defect in vitro and modest induction of endoplasmic reticulum (ER) stress. Identification of an intermediate-effect UMOD variant completes the spectrum of UMOD-associated kidney diseases and provides insights into the mechanisms of ADTKD and the genetic architecture of CKD. National Academy of Sciences 2022-08-10 2022-08-16 /pmc/articles/PMC9388113/ /pubmed/35947615 http://dx.doi.org/10.1073/pnas.2114734119 Text en Copyright © 2022 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Biological Sciences Olinger, Eric Schaeffer, Céline Kidd, Kendrah Elhassan, Elhussein A. E. Cheng, Yurong Dufour, Inès Schiano, Guglielmo Mabillard, Holly Pasqualetto, Elena Hofmann, Patrick Fuster, Daniel G. Kistler, Andreas D. Wilson, Ian J. Kmoch, Stanislav Raymond, Laure Robert, Thomas Eckardt, Kai-Uwe Bleyer, Anthony J. Köttgen, Anna Conlon, Peter J. Wiesener, Michael Sayer, John A. Rampoldi, Luca Devuyst, Olivier An intermediate-effect size variant in UMOD confers risk for chronic kidney disease |
title | An intermediate-effect size variant in UMOD confers risk for chronic kidney disease |
title_full | An intermediate-effect size variant in UMOD confers risk for chronic kidney disease |
title_fullStr | An intermediate-effect size variant in UMOD confers risk for chronic kidney disease |
title_full_unstemmed | An intermediate-effect size variant in UMOD confers risk for chronic kidney disease |
title_short | An intermediate-effect size variant in UMOD confers risk for chronic kidney disease |
title_sort | intermediate-effect size variant in umod confers risk for chronic kidney disease |
topic | Biological Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388113/ https://www.ncbi.nlm.nih.gov/pubmed/35947615 http://dx.doi.org/10.1073/pnas.2114734119 |
work_keys_str_mv | AT olingereric anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT schaefferceline anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT kiddkendrah anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT elhassanelhusseinae anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT chengyurong anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT dufourines anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT schianoguglielmo anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT mabillardholly anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT pasqualettoelena anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT hofmannpatrick anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT fusterdanielg anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT kistlerandreasd anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT wilsonianj anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT kmochstanislav anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT raymondlaure anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT robertthomas anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT eckardtkaiuwe anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT bleyeranthonyj anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT kottgenanna anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT conlonpeterj anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT wiesenermichael anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT sayerjohna anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT rampoldiluca anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT devuystolivier anintermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT olingereric intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT schaefferceline intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT kiddkendrah intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT elhassanelhusseinae intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT chengyurong intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT dufourines intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT schianoguglielmo intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT mabillardholly intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT pasqualettoelena intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT hofmannpatrick intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT fusterdanielg intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT kistlerandreasd intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT wilsonianj intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT kmochstanislav intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT raymondlaure intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT robertthomas intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT eckardtkaiuwe intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT bleyeranthonyj intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT kottgenanna intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT conlonpeterj intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT wiesenermichael intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT sayerjohna intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT rampoldiluca intermediateeffectsizevariantinumodconfersriskforchronickidneydisease AT devuystolivier intermediateeffectsizevariantinumodconfersriskforchronickidneydisease |